艾司氯胺酮用于成人严重烧伤患者自控智能镇痛:一项双盲随机试验,评估其对镇痛效果、胃肠功能及精神状态的影响
一项双中心随机对照试验纳入60例严重(20-50% TBSA)及大面积(≥50% TBSA)烧伤成人患者,1:1随机分组,比较术中及术后智能镇痛泵中使用艾司氯胺酮与标准麻醉的差异。分析55例,艾司氯胺酮组SAE 1-2级比例67.9% vs 对照组40.7%(p=0.022),运动痛NPR评分及每日阿片消耗量更低(p=0.033),胃肠恢复相当,总体睡眠质量可能改善。结论认为艾司氯胺酮用于严重烧伤围术期智能镇痛是安全的,可改善静息痛控制并降低阿片需求。
要点
- 艾司氯胺酮组SAE 1-2级比例67.9% vs 对照组40.7%,p=0.022。
- 艾司氯胺酮组运动痛NPR评分及每日阿片消耗量均低于对照组,p=0.033。
- 艾司氯胺酮组胃肠恢复与对照组相当,总体睡眠质量可能改善。
核心结论
- 艾司氯胺酮用于严重烧伤围术期智能镇痛是安全的,可改善静息痛控制并降低阿片需求。
研究设计与样本
- 双中心随机对照试验,60例严重(20-50% TBSA)及大面积(≥50% TBSA)烧伤成人患者按1:1随机分为两组,最终55例纳入分析。
- 治疗组术中接受艾司氯胺酮且术后静脉智能镇痛泵含艾司氯胺酮,对照组接受与治疗组相同干预但不含艾司氯胺酮。
- 主要终点为第28天或出院前一日评估的主观镇痛效果(SAE)。
主要发现
- 艾司氯胺酮组SAE 1-2级评分患者比例67.9% vs 对照组40.7%,p=0.022。
- 艾司氯胺酮组运动痛NPR评分低于对照组,p=0.033;每日阿片消耗量低于对照组,p=0.033。
- 艾司氯胺酮组胃肠恢复与对照组相当。
- 治疗组总体睡眠质量可能改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid consumption for analgesia in burn patients is enormous. Non-opioid analgesics for burn pain management may result in opioid sparing, reducing opioid-related adverse reactions and drug tolerance or addiction. METHODS: A dual-center, randomized controlled trial assessed Esketamine for the perioperative period in patients with severe [20-50 % total body surface area (TBSA)] and extensive (≥ 50 % TBSA) burns, comparing analgesia with standard anesthesia. Sixty patients were randomly allocated (1:1 ratio) to two arms. In the Treatment Arm, patients received intra-operative Esketamine and postoperative intravenous primary intelligent analgesia pump with Esketamine. Patients in the Control Arm received the same intervention as Treatment Arm without Esketamine. The primary endpoint was subjective analgesic efficacy (SAE) evaluated on Day 28 or the day before hospital discharge. Secondary outcomes included the postoperative Numeric Pain Rating (NPR) Scale at rest (NPRr) and during movement (NPRm) and opioid consumption. Gastrointestinal dysfunction Scores (GIDS) and serum markers of intestinal injury [intestinal fatty acid-binding protein 2 (iFabp2) and apolipoproteinA2 (ApoA2)] were measured in the 1st and 4th post-injury weeks. Depression and sleep quality were assessed by relevant questionnaires. RESULTS: Fifty-five patients were included in the analysis. Esketamine-treated Arm recorded a better analgesic efficacy than the Control Arm (proportion of patients with Grade 1 or 2 SAE scores, 67.9 % vs. 40.7 %, p = 0.022). Esketamine-treated patients had lower NPRm values (p = 0.033) and lower daily opioid consumption (p = 0.033) when compared with Controls. Esketamine-treated patients showed comparable gastrointestinal recovery to those in the Control Arm. The overall sleep quality might be improved in the Treatment Arm. CONCLUSIONS: Esketamine use is safe for perioperative primary intelligent analgesia of severe burns, resulting in improved resting pain control and lower opioid requirements. TRIAL REGISTRATION: The trial was registered at the Chinese Clinical Trial Registry (www.chictr.org.cn/) (ChiCTR2000034069).
引用
- He Q, Liu Q, Liang B, et al. Esketamine use for primary intelligent analgesia in adults with severe burns: A double-blind randomized trial with effects on analgesic efficacy, gastrointestinal function and mental state. Burns. 2024. PMID: 39317541. doi:10.1016/j.burns.2024.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。